Apadamtase alfa

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Takeda's Adzynma (rADAMTS13) as the first treatment for congenital thrombotic thrombocytopenic purpura (cTTP) in the UK for patients of all ages.

The global thrombocytopenia clinical trials landscape is expanding rapidly with over 25 pharmaceutical companies developing 25+ treatment therapies, according to recent market analysis.

Takeda Pharmaceutical is positioning three upcoming late-stage clinical trial readouts as a strategic "inflection point" to offset revenue losses from Vyvanse's generic competition.

• Takeda reported a 5% revenue increase in H1 2024, driven by an 18.7% growth in its Growth & Launch product portfolio, offsetting declines in VYVANSE sales. • The company raised its full-year guidance due to strong H1 performance and updated foreign exchange assumptions, while core operating profit margin reached 30.2%. • Takeda is actively investing in late-stage pipeline programs, including Phase 3 trials for TAK-861 (narcolepsy) and mezagitamab (IgA nephropathy). • Despite robust performance, Takeda anticipates challenges in H2 due to accelerated generic erosion of VYVANSE and increased R&D spending.

• Takeda reports a 13.4% revenue increase in the first half of FY2024, driven by Growth & Launch Products, including ENTYVIO, and geographical expansion with ADZYNMA and FRUZAQLA. • The company has initiated a Phase 3 trial for TAK-861 in narcolepsy type 1, showcasing advancements in its late-stage pipeline and commitment to developing life-transforming treatments. • Takeda upgrades its full-year forecasts, reflecting stronger-than-anticipated performance and revised foreign exchange assumptions, while planning to increase R&D investment in the second half. • Management Guidance for FY2024 has been upgraded, with Core Revenue expected to be flat to slightly increasing and Core Operating Profit decline in the mid-single-digit percentages.